Clinical Trial Update: Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Anlotinib with Osimertinib as second-line therapy for stage IIIb-IV non-small cell lung cancer with confi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN